Everything below concerns 脂肪酸酰化. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | Visual inspection under suitable light |
| Aqueous solubility | Soluble, pH dependent | Dissolves readily in neutral buffer |
| Storage temperature | 2-8 °C short term; -20 °C or below long term | Protect from light and moisture |
| Primary purity method | Reversed-phase HPLC | UV detection near 214 nm |
| Identity confirmation | LC-MS with peptide mapping | Mass accuracy within a few ppm |
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
==== Selective androgen receptor modulator-like activity ==== Although bicalutamide has been characterized as a silent antagonist of the AR in prostate tissue and other contexts, and despite its overall antiandrogenic profile, there is evidence that the drug may activate the AR to some degree in certain other tissues, such as muscle and bone among others. This would make bicalutamide a selective androgen receptor modulator (SARM), or a tissue-selective mixed agonist/antagonist or partial agonist of the AR, with antiandrogenic effects in some tissues and androgenic effects in other tissues, rather than a pure antiandrogen. This would be similar to certain other SARMs structurally related to bicalutamide, like enobosarm, which in animals have potent anabolic effects in muscle and bone but show partially agonistic or antagonistic effects in the prostate or seminal vesicles. Bicalutamide has been found to not oppose testosterone-induced increases in levator ani muscle weight in immature castrated male rats at doses of the drug (e.g., 0.08–2 mg/kg) that reduce or even completely block testosterone-induced prostate gland and seminal vesicle growth. In other studies, higher doses of bicalutamide (e.g., 10–30 mg/kg) reduced levator ani muscle weight (by ~40% or more) in gonadally intact male rats but had no effect on lean body mass (a surrogate of muscle mass), whereas castration reduced levator ani weight by around 70% and lean body mass by around 25%.
=== Lebanon === In June 2025 Lebanese authorities uncovered a major criminal network that smuggled and sold counterfeit cancer drugs, including fake immunotherapy medication like IMFINZI (durvalumab), through Beirut's airport. These medicines contained no active ingredients and were substituted for real chemotherapy drugs, placing patients' lives at risk. The judicial inquiry, led by Judge Dora al-Khazen, has resulted in at least five arrests, including Mohamad Khalil (brother of former Finance Minister Ali Hassan Khalil), his ex-wife (a Beirut-area pharmacist), and a security officer who facilitated the smuggling. The scandal triggered emergency governmental action, widespread pharmacy raids, and significant public outrage, as lawmakers warned that up to one-third of medicines in Lebanon could be fake.
=== Diagnosis === It is difficult to differentiate the effects of low level metal poisoning from the environment with other kinds of environmental harms, including nonmetal pollution. Generally, increased exposure to heavy metals in the environment increases the risks for several diseases.
=== Detergents, cosmetics, etc. === Sulfation is widely used in the production of consumer products such as detergents, shampoos, and cosmetics. Since the sulfate group is highly polar, its conjugation to a lipophilic "tail" gives surfacant-like properties. Well known sulfates are sodium lauryl sulfate and sodium laureth sulfate. Alkylsulfate are produced from alcohols by reaction with chlorosulfuric acid:
=== Invention === The invention of gas chromatography is attributed to Anthony T. James and Archer J.P. Martin at the National Institute for Medical Research in Mill Hill, London in 1951. Their gas chromatograph used partition chromatography as the separating principle, rather than adsorption chromatography. The popularity of gas chromatography quickly rose after the development of the flame ionization detector. Martin and another one of their colleagues, Richard Synge, with whom he shared the 1952 Nobel Prize in Chemistry, had noted in an earlier paper that chromatography might also be used to separate gases. Synge pursued other work while Martin continued his work with James. In trying to commercialize the technology shortly after its invention, Griffin and George Ltd. based in London manufactured and sold gas chromatographs in 1954. Other companies, such as Pye Unicam based in Cambridge and companies based in the US, would follow in 1955 and 1956.
Sources: en.wikipedia.org
At the end of the 1950s, the USSR constructed the first satellite—Sputnik 1, which marked the beginning of the Space Race—a competition to achieve superior spaceflight capability with the United States. This was followed by other successful satellites, most notably Sputnik 5, where test dogs were sent to space. On 12 April 1961, the USSR launched Vostok 1, which carried Yuri Gagarin, making him the first human to ever be launched into space and complete a space journey. The first plans for space shuttles and orbital stations were drawn up in Soviet design offices, but personal disputes between designers and management prevented their development. In terms of the Luna program, the USSR only had automated spacecraft launches with no crewed spacecraft. The N1—a Super heavy-lift launch vehicle intended to match the American Saturn V for a Soviet crewed moon landing—failed all four of its test launches, and the 'Moon' part of Space Race was won by the Americans. The Soviet public's reaction to the American moon-landing was mixed. The Soviet government limited the release of information about it, which affected the reaction. A portion of the populace did not give it attention, and another portion was angered. In the 1970s, specific proposals for the design of a space shuttle emerged, but shortcomings, especially in the electronics industry (rapid overheating of electronics), postponed it till the end of the 1980s. The first shuttle, the Buran, flew in 1988, but without a human crew. Another, Ptichka, endured prolonged construction and was canceled in 1991.
== Etymology == The etymology of the common name "emu" is uncertain, but is thought to have come from an Arabic word for large bird that was later used by Portuguese explorers to describe the related cassowary in Australia and New Guinea. Another theory is that it comes from the word "ema", which is used in Portuguese to denote a large bird akin to an ostrich or crane. In Victoria, some terms for the emu were Barrimal in the Dja Dja Wurrung language, myoure in Gunai, and courn in Jardwadjali. The birds were known as murawung or birabayin to the local Eora and Darug inhabitants of the Sydney basin.
Isoflavonoid synthase is a cytochrome P450 protein containing heme. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate (NADPH).
The following is a list of notable proteins that are produced from recombinant DNA, using biomolecular engineering. In many cases, recombinant human proteins have replaced the original animal-derived version used in medicine. The prefix "rh" for "recombinant human" appears less and less in the literature. A much larger number of recombinant proteins is used in the research laboratory. These include both commercially available proteins (for example most of the enzymes used in the molecular biology laboratory), and those that are generated in the course specific research projects.
Sources: en.wikipedia.org
=== Prokaryotic === Predicted serpin genes are sporadically distributed in prokaryotes. In vitro studies on some of these molecules have revealed that they are able to inhibit proteases, and it is suggested that they function as inhibitors in vivo. Several prokaryote serpins are found in extremophiles. Accordingly, and in contrast to mammalian serpins, these molecules possess elevated resistance to heat denaturation. The precise role of most bacterial serpins remains obscure, although Clostridium thermocellum serpin localises to the cellulosome. It is suggested that the role of cellulosome-associated serpins may be to prevent unwanted protease activity against the cellulosome.
=== Methodology === A sample of water is collected in the field in a vial without headspace and capped with a Teflon septum or crimp top to minimize the escape of volatile gases. It is beneficial to store the bottles upside down to further minimize loss of analytes. Before analysis begins, the sample is brought to room temperature and temperature is recorded. In the laboratory, a headspace is created by displacing water with high purity helium. The bottle is then shaken upside down for a minimum of five minutes in order to equilibrate the dissolved gases into the headspace. It's important to note that the bottle must be kept upside down for the remainder of analysis if manually injected. A known volume of headspace gas is then injected onto a gas chromatographic column. An automated process can also be utilized. Individual components (gases) are separated and detected by either a thermal conductivity detector (TCD), a flame ionization detector (FID), or an electron capture detector (ECD). Using the known temperature of the sample, the bottle volume, the concentrations of gas in the headspace (as determined by GC), and Henry's law constant, the concentration of the original water sample is calculated.
In October 2025, Wander was indicted in the U.S. District Court for the Southern District of New York on federal charges of conspiracy to commit wire fraud, wire fraud, conspiracy to commit securities fraud, and securities fraud. Prosecutors alleged that Wander and his associates defrauded lenders and investors of nearly $500 million through a scheme involving fabricated financial statements, doctored records, and double-pledged collateral. New allegations were made in a superseding indictment on June 30, 2026, further alleging diversion of loan funds, fabrication of financial records, and witness tampering.
Sources: en.wikipedia.org
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.
Mass spectrometry and peptide mapping are commonly used, often alongside chromatographic retention time comparison. No single technique covers both sequence and higher-order structure.
Aggregation is monitored because it can alter activity and may influence immune responses. Size-exclusion chromatography and related techniques are used to quantify it.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.